Structure and function of oncogene-transfected immortal cells by Kavsan, V.M. et al.
MINIREVIEWS
UDC 577.21 : 577.214 + 616-006.48
Structure and function of oncogene-transfected 
immortal cells
V. M. Kavsan1, T. A. Kulagova2, T. A. Kuznetsova3, G. N. Semenkova3, 
A. A. Stepanenko1, Y. S. Vassetzky4 
1State Key Laboratory of Molecular and Cellular Biology, 
Institute of Molecular Biology and Genetics, NAS of Ukraine
150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
2Belarusian State University
4, Nezavisimosti avenue, Minsk, Republic of Belarus, 220030 
3N. I. Pirogov Russian National Research Medical University
1, Ostrovitianov Str., Moscow, Russian Federation, 117997
4CNRS UMR8126, Paris-Sud University, Gustave Roussy Institute
114, rue Edouard Vaillant, 94805 Villejuif Cedex-France
Previously we have characterized a new oncogene CHI3L1, overexpressed in the glioblastoma and the malig-
nant 293_CHI3L1 cells, stably producing the CHI3L1 angiogenic oncoprotein. The 293_CHI3L1 cells prolife-
rated faster and acquired a higher ability for anchorage-independent growth. Here, we report the atomic force
microscopy data and functional characteristics of these cells. The constitutive CHI3L1 expression leads to the in-
creased resistance to the damages by oxidative substances and promotes the chromosome instability in the 293
cells. According to the data of the last clinical investigations, anti-cancer therapy should be  targeted  not  at  the in- 
dividual genes, but  at  the pathological effects they caused. We propose a complex treatment of gliomas inclu-
ding multi-target inhibitors, which can be delivered to the brain tumor by a specific nanoparticle vector.
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Previously we have characterized a new oncogene
CHI3L1, overexpressed in the glioblastoma [1], and 
the malignant 293_CHI3L1 cells, stably producing the 
CHI3L1 oncoprotein [2].  The 293_CHI3L1 cells pro-
liferated faster and acquired a higher ability to ancho-
rage-independent growth than the 293 cells, which
were stably transfected with an «empty» vector with-
out a CHI3L1 cDNA insert. Here we report the atomic
force microscopy data and functional characteristics of
these cells.
Atomic force microscopy showed that the 293 cells, 
generated by transformation of human embryonic kid- 
ney cells with sheared adenovirus 5 DNA [3] and trans-
fected by an «empty» vector (293_pcDNA3.1 cells),
had a round body with 3–5 long outgrowths, which
joined several neighbor cells with free space between
them. The space occupied by the net of such cells remin- 
ded the organization of neuronal nets that is one more
confirmation of the neuronal origin of the 293 cells [4].
CHI3L1 production induced the morphological changes:
increased space of cell body on the substrate, bigger cell
height and body volume, different distribution on the
substrate, loss of long outgrowths, spindle shape (they are
stretched and sharp-edged with short wide outgrowths
for the contact with neighbor cells) accompanied by re-
organization of actin cytoskeleton, a major mediator of 
cell migration and invasion (Fig. 1). 
The expression of the CHI3L1 gene leads to an in-
creased resistance of  the 293_CHI3L1 cells to the oxi-
dants (H2O2, sodium hypochloride and peroxynitrite do-
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nor SIN-1). The rate constant of H2O2 scavenging in the
293_CHI3L1 cells is 2.7-fold higher than that in the im- 
mortalized but not yet malignant 293 cells. It was revea-
led that the 293_CHI3L1 cells generated reactive oxy-
gen species (ROS) under menadione action more inten-
sively than the original cells. The activities of enzymes
participating in the menadione-induced generation of
ROS are regulated by the JNK-mitogen activated pro-
tein kinase and phosphatidylinositol-3-kinase in the
293_CHI3L1 cells. The elevated levels of reduced gluta-
thione, a major cellular antioxidant, may at least partial- 
ly explain an increased resistance of the 293_CHI3L1
cells to the oxidative stress. A higher resistance of the
cancer cells to H2O2 reduced their vulnerability to the ROS 
action. The addition of antioxidant drugs may even in-
crease this effect. These results are in a good correspon- 
dence with the recently published conception of Wat-
son [5] about the importance of the ROS and antioxi-
dants in the tumor development. 
The combinatorial chemotherapy came of age in the
1970s and its achievements and failures are well docu-
mented by now. Of course, much remains to be learned
why it is active in certain situations and decidedly inac- 
tive in others; variable apoptotic threshold is a possible
explanation. The unstable genome is more likely gene-
rates resistant variants, which are then selected to sur-
vive. «The Heng-Duesberg model, or any other model
identifying accelerated macroevolution as the central
fact of cancer, would also account for the rapid emer-
gence of resistant variants, as would «adaptive resilien- 
ce» as an ancient trait» [6]. In our experiments the 293
cells (human embryonic kidney cells  known as HEK-
293) were used as control original cells. They are im-
mortal and, like other immortalized cells, they could in- 
definitely proliferate and their proliferation ability de-
pended on nutrients and growth factors. However, they
could not grow over one another in cell culture (contact 
inhibition), improperly formed colonies in soft agar (an-
chorage-dependent growth), and did not form tumors
when injected into the immune competent rodents. All
these characteristics appeared with additional chromo-
some changes in the 293_CHI3L1 cells (Fig. 2).
A main driver of tumor evolution is the genetic he-
terogeneity, which is fostered by the chromosome in-
stability (CIN). Here we evidence that constitutive ex-
pression of CHI3L1 promotes chromosome instability
in 293 cells. The modal chromosome number in the
293_CHI3L1 clone 1 (69–73) and in the 293_CHI3L1
clone 2 cells (72–74) was different from that in the pa-
rental 293 cells (67–72). Interline whole chromosome
heterogeneity was manifested in all three cell lines. A
number of new distinct marker chromosomes were ob-
served in the CHI3L1-expressing clones. The array com- 
parative genome hybridization (aCGH) was used to ana- 
lyze the sub-chromosomal alterations in these cell lines.
The spectrum of cytoband gains and losses in the 293_
CHI3L1 clone 1 and clone 2 cells is similar but differs
from the parental 293 cells. The karyotypes of these cells
are unique, completely different from other immortal
and malignant cells in culture as well as from all tumor
cells. According to Duesberg et al. [6], cancer cell is a
unique unicellular eukaryotic species and, moreover, li-
ke Vincent proposed [7], cancer may be seen as a entire
bunch of different (unicellular) species, because there
are hardly two cancer cells with exactly the same genome.
CHI3L1 similarly to other oncogenes was like a trig-
ger in the transformation of the immortal 293 cells into
the malignant 293_CHI3L1 cells. However, the census
of cancer genes includes about 500 human tumor-asso-
ciated genes. Nevertheless, an overwhelming amount
of diverse molecular information offers only limited un-
derstanding of general mechanisms of the cancer deve-
lopment. According to the new evolutionary karyotypic 
concept of cancer, tumor evolution is a macro-evolutio- 
nary process, where karyotype or stochastic genome-le- 
vel alterations play a dominant role. The engine for ka-
ryotype evolution is the chromosome instability, which
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Fig. 1. AFM images of 293_pcDNA3.1 and 293_CHI3L1 cells
results from persistent defects in mitotic fidelity and im-
plies both total and segmental chromosome instability
(translocations, deletions, and amplifications). CIN allows 
quick changes in doses of multiple genes and represents 
early and causative event in cancer progression which
significantly correlates with the acquired therapy resis-
tance (Duesberg et al. [6], reviewed in [8]).
The single markers and targets alone do not have a
significant clinical value, high heterogeneity of glial tu-
mors requires the simultaneous analysis of many genes
and the therapy aimed not at the individual genes, but at 
the physiological effect they caused. One of such phy-
siological effects is angiogenesis, which plays a key ro- 
le in tumor vascularization. In anticancer therapy, consi- 
derable attention is paid to the anti-angiogenic drugs.
Previously, it has been shown that CHI3L1 has a strong 
angiogenic effect. We found that knockdown of CHI3L1
in the 293_CHI3L1 cells by specific siRNAs decreased
the production of CHI3L1 to 10 %. Nevertheless, the
success of angiogenic drugs in clinic is a temporary one:
drug resistance, tumor reemergence, and rapid appea-
rance of new vessels develop at the end of therapy. An-
giogenic (oncogenic) redundancy is a significant ob-
stacle to the success of targeting therapy. It is supposed
that simultaneous treatment with the anti-CHI3L1 and
anti-VEGF drugs should give better result. Bradykinin
antagonists and azolidinone derivatives were shown to
be quite promising as new potential anti-cancer com-
pounds for the complex therapy at least in the cell cultu-
res and  the in vivo rat model experiments. The search
for new targets was performed by cluster analysis of the 
data on gene expression in the glioblastoma and normal 
brain samples by self-organising Kohonen’s maps. 
For multiple-target drugs delivery to the gliomas we
are planning to use a specific vector, Polycefin [9] com- 
prising necessary features: penetration across the blood-
brain barrier and tumor-normal brain barrier, highly-se-
lective accumulation of the therapeutic agent in tumors, 
lack of toxicity, non-immunogenicity, biodegradation,
stability in the bloodstream. Additionally the inhibitors 
of multiple molecular targets should be easily attached
to one vector molecule.
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Ñòðóê òó ðà ³ ôóíêö³ÿ ³ììîð òàë³çî âà íèõ êë³òèí, 
òðàíñ ôîð ìî âà íèõ îíêî ãå íîì 
Â. Ì. Êàâ ñàí, Ò. À. Êó ëà ãî âà, Ò. À. Êóç íå öî âà, 
Ã. Ì. Ñå ìåí êî âà, À. À. Ñòå ïà íåí êî, ª. Ñ. Âàñ åöü êèé
Ðå çþ ìå
Ðàí³øå íàìè îõà ðàê òå ðè çî âà íî íî âèé îíêî ãåí CHI3L1, ÿêèé ñó ïåð-
åêñïðå ñóºòüñÿ â ãë³îá ëàñ òîì³ òà çëî ÿê³ñíèõ êë³òè íàõ 293_CHI3L1, 
ùo ñòàá³ëüíî ïðî äó êó þòü àíã³îãåí íèé îíêîá³ëîê CHI3L1. Êë³òè-
íè 293_CHI3L1 ïðîë³ôå ðó þòü øâèä øå ³ íà áó âà þòü á³ëüøî¿ çäàò- 
íîñò³ äî íå çà ëåæ íî ãî â³ä îñíî âè ðîñ òó. Íà âå äå íî äàí³ àòîì íî-
ñè ëî âî¿ ì³êðîñ êîï³¿ òà ôóíêö³îíàëüí³ õà ðàê òå ðèñ òè êè çà çíà ÷å -
íèõ êë³òèí. Êîí ñòè òó òèâ íà åêñïðåñ³ÿ CHI3L1 ï³äâè ùóº ñò³é-
ê³ñòü äî ïî øêîä æåíü ðå ÷î âè íà ìè-îêèñ íþ âà ÷à ìè ³ ñïðèÿº íå ñòà-
á³ëüíîñò³ õðî ìî ñîì ó êë³òè íàõ 293. Çà äà íè ìè îñòàíí³õ êë³í³÷íèõ
âèï ðî áó âàíü, ïðî òè ðà êî âà òå ðàï³ÿ ïî âèí íà áóòè íàö³ëåíà íå íà
³íäèâ³äó àëüí³ ãåíè, à íà ñïðè ÷è íåí³ íèìè ïà òî ëîã³÷í³ åôåê òè. Ìè
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Fig. 2. Representative karyograms of the 293 cells (A) and 293_CHI3L1 (clone 2) cells (B). Abnormal chromosomes are marked with red lines
above corresponding chromosomes
ïðî ïî íóºìî êîì ïëåê ñíå ë³êó âàí íÿ ãë³îì ³ç çà ëó ÷åí íÿì áà ãà òîì³-
øåí íèõ ³íã³á³òîð³â, ÿê³ ìîæ íà äî ñòâëÿ òè äî ïóõ ëèí ãî ëîâ íî ãî
ìîç êó ñïå öèô³÷íèì âåê òî ðîì íà îñíîâ³ íà íî ÷àñ òîê.
Êëþ ÷îâ³ ñëî âà: îíêî ãåí CHI3L1, àòîì íî-ñè ëî âà ì³êðîñ êîï³ÿ,
àêòèâí³ ôîð ìè êèñ íþ (ÀÔÊ), êë³òèíè 293 (HEK-293), êîìá³íàòîð-
íà õ³ì³îò å ðàï³ÿ, õðî ìî ñîì íà íå ñòàá³ëüí³ñòü (CIN).
Ñòðóê òó ðà è ôóíê öèÿ èì ìîð òà ëè çî âàí íûõ êëå òîê, 
òðàíñ ôîð ìè ðî âàí íûõ îíêî ãå íîì
Â. Ì. Êàâ ñàí, Ò. À. Êó ëà ãî âà, Ò. À. Êóç íå öî âà, 
Ã. Í. Ñå ìåí êî âà, À. À. Ñòå ïà íåí êî, Å. Ñ. Âàñåö êèé
Ðå çþ ìå
Ðà íåå íàìè îõà ðàê òå ðè çî âàí íî âûé îíêî ãåí CHI3L1, ñó ïåðýêñ-
ïðåñ ñè ðó þ ùèé ñÿ â ãëè îá ëàñ òî ìå è çëî êà ÷åñ òâåí íûõ êëåò êàõ
293_CHI3L1, ñòà áèëü íî ïðî äó öè ðó þ ùèx àí ãè î ãåí íûé îíêî áå ëîê
CHI3L1. Êëåò êè 293_CHI3L1 ïðî ëè ôå ðè ðó þò áûñ òðåå è ïðè îá ðå-
òàþò áîëü øóþ ñïî ñîá íîñòü ê íå çà âè ñè ìî ìó îò ïîä ëîæ êè ðîñ òó.
Ïðè âå äå íû äàí íûå àòîì íî-ñè ëî âîé ìèê ðîñ êî ïèè è ôóíê öè î íàëü -
íûå õà ðàê òå ðèñ òè êè óêà çàí íûõ êëå òîê. Êîí ñòè òó òèâ íàÿ ýêñ -
ïðåñ ñèÿ CHI3L1 ïî âû øà åò óñòîé ÷è âîñòü ê ïî âðåæ äå íè ÿì âåùå-
ñòâà ìè-îêèñ ëè òå ëÿ ìè è ñïî ñî áñòâó åò íå ñòà áèëü íîñ òè õðî ìî -
ñîì â êëåò êàõ 293. Ïî äàí íûì ïî ñëåä íèõ êëè íè ÷åñ êèõ èñ ïû òà íèé, 
ïðî òè âî ðà êî âàÿ òå ðà ïèÿ äîë æíà áûòü íà öå ëå íà íå íà èí äè âè äó -
àëü íûå ãåíû, à íà âû çû âàe ìûå èìè ïà òî ëî ãè ÷åñ êèå ýô ôåê òû. Ìû 
ïðåä ëà ãà åì êîì ïëåê ñíîå ëå ÷å íèå ãëè îì ñ ïðè âëå ÷å íè åì ìóëü òèìè-
øåí íûõ èí ãè áè òî ðîâ, êî òî ðûå ìîæ íî äîñ òàâ ëÿòü ê îïó õî ëÿì ãî-
ëîâ íî ãî ìîç ãà ñïå öè ôè ÷åñ êèì âåê òî ðîì íà îñíî âå íà íî ÷àñ òèö.
Êëþ ÷å âûå ñëî âà:  îíêî ãåí CHI3L1, àòîì íî-ñè ëî âàÿ ìèê ðîñ êî -
ïèÿ, àê òèâ íûå ôîð ìû êèñ ëî ðî äà (ÀÔÊ), êëåò êè 293 (HEK-293),
êîì áè íà òîð íàÿ õè ìè î òå ðà ïèÿ, õðî ìî ñîì íàÿ íå ñòà áèëü íîñòü
(CIN).
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